Ascendis Pharma As Stock Probability of Future Stock Price Finishing Over 134.28
| ASND Stock | USD 140.31 1.52 1.10% |
Ascendis |
Ascendis Pharma Target Price Odds to finish over 134.28
The tendency of Ascendis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 134.28 in 90 days |
| 140.31 | 90 days | 134.28 | about 39.79 |
Based on a normal probability distribution, the odds of Ascendis Pharma to stay above $ 134.28 in 90 days from now is about 39.79 (This Ascendis Pharma AS probability density function shows the probability of Ascendis Stock to fall within a particular range of prices over 90 days) . Probability of Ascendis Pharma AS price to stay between $ 134.28 and its current price of $140.31 at the end of the 90-day period is about 26.47 .
Given the investment horizon of 90 days Ascendis Pharma has a beta of 0.53. This suggests as returns on the market go up, Ascendis Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Ascendis Pharma AS will be expected to be much smaller as well. Additionally Ascendis Pharma AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Ascendis Pharma Price Density |
| Price |
Predictive Modules for Ascendis Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ascendis Pharma AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ascendis Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ascendis Pharma is not an exception. The market had few large corrections towards the Ascendis Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ascendis Pharma AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ascendis Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 0.53 | |
σ | Overall volatility | 7.07 | |
Ir | Information ratio | -0.05 |
Ascendis Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ascendis Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ascendis Pharma AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Ascendis Pharma AS generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Sage Therapeutics Surges 12.2 percent Is This an Indication of Further Gains |
Ascendis Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ascendis Stock often depends not only on the future outlook of the current and potential Ascendis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ascendis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 56.3 M | |
| Cash And Short Term Investments | 399.4 M |
Ascendis Pharma Technical Analysis
Ascendis Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Ascendis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Ascendis Pharma AS. In general, you should focus on analyzing Ascendis Stock price patterns and their correlations with different microeconomic environments and drivers.
Ascendis Pharma Predictive Forecast Models
Ascendis Pharma's time-series forecasting models is one of many Ascendis Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Ascendis Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Ascendis Pharma AS
Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Ascendis Pharma AS generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Sage Therapeutics Surges 12.2 percent Is This an Indication of Further Gains |
Check out Ascendis Pharma Backtesting, Ascendis Pharma Valuation, Ascendis Pharma Correlation, Ascendis Pharma Hype Analysis, Ascendis Pharma Volatility, Ascendis Pharma History as well as Ascendis Pharma Performance. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.76) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.